Sean Sheridan, in an article published in Law360, provides an overview of recent high-profile court cases that have addressed the issue of patentable subject matter. The article also describes how these decisions are changing patent examination at the U.S. Patent and Trademark Office and discusses how the changing scope of patent-eligible subject matter may impact intellectual property valuations and transactions in the life sciences field. To read the article, click the link below.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...